anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Certain cutaneous signs and symptoms of treatment such as erythema, dryness, scaling, burning, or pruritus may be experienced with use of Adapalene Cream, 0.1%. These are most likely to occur during the first two to four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication. Depending upon the severity of these side effects, patients should be instructed to reduce the frequency of application or discontinue use. 

If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during use of adapalene. Patients who normally experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with adapalene. 

Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. The product should not be applied to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method should be avoided on skin treated with adapalene.
PURPOSE:To improve the long-period preservation stability by incorporating a specified nonionic surfactant, a specified stearic ester and a specified emulsification assistant into the titled oil droplet-in-water type emulsion composition contg. a specified vegetable crude drug. CONSTITUTION:The oil droplet-in-water type emulsion composition contg. a crude drug derived from a liliaceous succulent plant such as aloe or a crude drug derived from a cucurbitaceous vegetable such as cucumber, Luffa cylindrica and Trichosanthes cucumeroides is prepared. A lipophilic nonionic surfactant having 2.0-5.0 HLB and a polyethylene glycol stearic ester having 14-18 HLB are incorporated into the composition. Glyceryl monostearate, glyceryl isostearate, etc., are exemplified as the lipophilic nonionic surfactant and lauryl alcohol, stearyl alcohol, etc., are exemplified as the higher alcohol.
Individuals with long COVID report diverse symptoms lasting weeks or months after initial infection, causing significant psychosocial distress. Navigating health care interactions are often difficult for these individuals due to the diffuse nature of their symptoms, a lack of effective treatment options, and skepticism from some providers. To better understand these challenges, this study sought to further describe the lived experience of individuals with long COVID. A survey was conducted with individuals evaluated for long COVID at a specialty clinic (n = 200), which included questions about prior conditions, symptoms, use of medical and support services, and information and resource needs. Participants reported a mean of 10.75 persistent symptoms, the most common being fatigue and difficulty concentrating, with broad effects on daily functioning. Participants saw a mean of 5.92 providers for treatment of their symptoms, and 88.5% identified health care providers as a trusted source of information. Interest in research findings (60.5%) and opportunities for participation (47.5%) were moderate and varied by COVID vaccination status. Unvaccinated individuals (n = 27) also reported less trust in government sources of information, less college education, lower household income, and greater likelihood of having public insurance. Our findings suggest that individuals with long COVID experience many ongoing and complex symptoms with diverse effects on daily living; that health care providers are an important source for public health messaging about long COVID; and that unvaccinated individuals are likely to have differing needs and receptiveness to information than vaccinated individuals with long COVID.
The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
This article considers the addition of comprehensive 24-chromosomal microarray (CMA) analysis of products of conception (POC) to a standard evaluation for recurrent pregnancy loss (RPL) to help direct treatment towards expectant management versus IVF with preimplantation genetic testing for aneuploidies (PGT-A). The review included retrospective data from 65,333 miscarriages, a prospective evaluation of 378 couples with RPL who had CMA testing of POC and the standard workup, and data from an additional 1020 couples who were evaluated for RPL but did not undergo CMA testing of POC. Aneuploidy in POC explained the pregnancy loss in 57.7% (218/378) of cases. In contrast, the full RPL evaluation recommended by the American Society for Reproductive Medicine identified a potential cause in only 42.9% (600/1398). Combining the data from the RPL evaluation and the results of genetic testing of POC provides a probable explanation for the loss in over 90% (347/378) of women. Couples with an unexplained loss after the standard evaluation with POC aneuploidy accounted for 41% of cases; PGT-A may be considered after expectant management. Conversely, PGT-A would have a limited role in those with a euploid loss and a possible explanation after the standard workup. Categorizing a pregnancy loss as an explained versus unexplained loss after the standard evaluation combined with the results of CMA testing of POC may help identify patients who would benefit from expectant management versus PGT-A.
INTRODUCTION: Pacemaker-mediated tachycardia is a known arrhythmia in patients with dual chamber pacemakers and defibrillators and intact ventriculoatrial (VA) conduction. We report a case of pacemaker-mediated reentrant arrhythmia (PMRA) in a patient with an atrioventricular (AV) synchronous leadless pacemaker.
METHODS AND RESULTS: A 91-year-old female presented with 2:1 AV conduction and received an AV synchronous leadless pacemaker. She had atrial mechanical sense-ventricular paced beats between heart rates of 80-100 bpm more than 80% of the time. She was found to have a new cardiomyopathy and was referred for placement of biventricular pacemaker. At the time of device implantation, her electrocardiogram showed ventricular pacing with a short RP interval and superiorly directed P waves. Changes in the ventricular pacing rate resulted in changes in the atrial rate. Following device placement, her heart rate decreased to the lower rate limit of her pacemaker. The atrial mechanical sense impulse most likely was generated by a retrograde conducted P wave resulting in near incessant PMRA.
CONCLUSION: PMRA may occur in patients who receive an AV synchronous leadless pacemaker with intact VA conduction and sinoatrial node dysfunction. Due to the lower rates of PMRA, this arrhythmia may be underrecognized. Interventions for and implications of PMRA need further investigation.
The present invention relates to an ionophore antibiotic composition in the form of a water dispersible granule which is a dry flowable formulation capable of direct dispersion in the drinking water of animals (i.e. via trough treatment). The ionophore antibiotic remains in a substantially stable solution uniformly dispersed in the drinking water for up to 62 days and thus provides a safe and practical form of treatment. The formulation is also capable of being mixed with water for oral administration by drenching. The water dispersible granule composition comprises at least one ionophore antibiotic (preferably monensin), at least one filler-binder, at least one surfactant, at least one dispersing agent, and at least one disintegrant. The ionophore antibiotic is preferably micronized before inclusion in the composition. The invention also relates to a method of manufacturing the composition comprising a dry milling step to reduce the particle size of the ionophore antibiotic to less than 30 microns, a mixing step and a dry granulation step.
Attention Deficit Hyperactivity Disorder (ADHD) is characterized by symptoms of impulsivity, inattention, and hyperactivity that emerge in childhood and frequently persist into adulthood. These symptoms are accompanied by deficits in cognitive control and risky decision making that can lead to negative psychosocial and health-related outcomes. With advances in the neuroimaging field, researchers are learning where and how self-control over decisions and behaviors is executed in the brain. This work points to the central role of neural activity in the dorsolateral prefrontal cortices (DLPFC) in self-control processes that contribute to healthy choices. Emerging evidence shows that activity in the prefrontal cortices and cognitive control circuits can be modulated using a noninvasive and safe intervention: repetitive TMS. This within-subject proof of concept study will investigate whether 20 sessions of TMS (versus sham stimulation) can enhance executive cognitive function in adults with ADHD.
Potassium Chloride in 0.9% Sodium Chloride Injection provides electrolytes and is a source of water for hydration. It is capable of inducing diuresis depending on the clinical condition of the patient.

Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of acid-base equilibrium of body fluid.

Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.
There are no currently available pharmacologic treatments for cocaine abuse and/or dependence and the unmet medical need is growing. In collaboration with the National Institute on Drug Abuse (NIDA), Alkermes, Inc. is investigating a fixed-dose combination product consisting of ALKS 33 (also referred to as RDC-0313) and buprenorphine (ALKS 33-BUP) for the treatment of cocaine abuse and/or dependence (Grant Number R01DA031000).

This is a randomized, double-blind, placebo-controlled, parallel design inpatient study. Eligibility will be established which includes responses to cocaine infusions at baseline, prior to study drug administration. Approximately 30 opioid-experienced cocaine abusers will be randomized 1:1:1 to receive study drug. Study drug will be administered once daily for 10 consecutive days. Pharmacodynamic assessments and drug-drug interactions will be closely monitored during the study. Following study drug administration, subjects will receive cocaine infusions to evaluate the effect of treatment on the subjective effects and the PK/PD of cocaine. Subjects will be discharged from the clinical research unit 2 days after the last infusion of cocaine. Subjects will return for follow-up between 7 and 14 days after discharge. The full study will take subjects approximately 28 days, with 17 days of inpatient stay.
Disclosed is a method for dissolving cholesterol-rich calculi, most preferably gallstones in vivo, comprising contacting the calculus with a fluid compound of the formula R-X, R having 2 to 4 carbon atoms with substituents consisting of hydrogen of halogen, X being halogen, and wherein if X is fluorine, at least one substituent is selected from the group consisting of hydrogen, chlorine, bromine, or iodine. Usually R-X is 2-bromo-2-chloro-1,1,1-trifluoroethane (also referred to as Halothane.) Other compounds of particular interest are 2-chloro-1,2,-dibromo-1,1,2-trifluoroethane, 1-bromo-2-chloro-1,1,2-trifluoroethane, 2,3-dibromo-1,1,1-trifluoropropane, 2-iodo-1,1,1-trifluoroethane, 1,2-dichloro-1,1-difluoroethane, 1,1,2-trichloro-2,3,3-trifluorocyclobutane, hexafluoro-1,1,3,4,-tetrachlorobutane, 1,1,1-trichlorotrifluoroethane, and 1,2-dibromo-tetrafluoroethane. Furthermore, Halothane and MtBE in combination effectively dissolve cholesterol-rich calculi. Finally, dissolution can be enhanced by adding to the dissolution solvent up to about 50 percent by volume of a lower alcohol. Usually the lower alcohol is ethanol in the amount of about 5 to 40, usually 10 to 30 and preferably about 10 percent by volume. Most preferably in this case, R-X is Halothane or 1,1,1-trichlorotrifluoroethane. Dissolution using previously known solvents such as MtBE is also enhanced by such addition of lower alcohols. In addition, the practical use of MtBE for dissolution can be improved by the addition of the compounds described above as R-X, particularly Halothane, and usually at levels of about 5 to 50 volume percent Halothane.
This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, \& completed the follow surveys at 12, 18, \& 24 months of age.
<P>PROBLEM TO BE SOLVED: To improve the reliability of data by managing evaluation of the effects and of side effects of a drug for each haplotype, and reflecting prescription results collected after marketing.  <P>SOLUTION: The experiment data of new medicine presented by a pharmaceutical company are registered in an initial evaluation chart database 14 and a use evaluation chart database 15. Each of the databases 14 and 15 manages the effects and side effects of the drug for each haplotype. After selling the new medicine, the drug corresponding to the diseases or haplotype of a patient are selected by referring to the use evaluation chart database 15 in a medical facility such as a hospital. Also, the treatment results by prescription are digitized by an RNA chip or the like, and transmitted to a center 10 for statistical processing, and the use evaluation chart database 15 is updated.  <P>COPYRIGHT: (C)2004,JPO
Participants will receive JNJ-73763989 subcutaneous (SC) injections and single dose of programmed cell death protein receptor-1 (PD-1) inhibitor as intravenous (IV) infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide \[TAF\] or entecavir \[ETV\]).
Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
Participants from the experimental group will receive a hybrid Mindfulness-based Dementia Caregiving Program (MBDCP). It is a 6-week program. In the 1st, 2nd and 6th session, it is delivered through face to face, while in the 3rd, 4th and 5th sessions, it will be delivered via online approach.
PURPOSE: To obtain a medicine preparation useful for treating an endogenous polypeptide-related pathological state, containing enkephalinase or its functional derivative as a carrier. CONSTITUTION: This medicine preparation contains enkephalinase or its functional derivative (e.g. a derivative deficient in a cytoplasm region and/or a transmembrane) and a pharmacological permissible carrier. Tachykinins (e.g. substance P, neurokinin A and physalaemin), a chemotactic peptide, angiotensin I, bombesin, etc., may be cited as the endogenous polypeptide. Endogenous polypeptide-related diseases includes inflammation, allergic dermatitis, respiratory tract disease, tumor, renal hypertension, etc. The preparation is applied by administration such as intramuscular administration, intravenous administration or intrapulmonary inhalation. A dose of enkephalinase is 0.001-25mg/kg, especially 0.01 20mg/kg.
BACKGROUND: Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation is a rare autosomal dominant disease caused by mutations in KIF11 which disrupt EG5 protein function, impacting the development and maintenance of retinal and lymphatic structures due to its expression in the retinal photoreceptor cilia. The primary ocular finding in MCLMR is chorioretinopathy. Additional features can include microphthalmia, angle-closure glaucoma, persistent hyperplastic primary vitreous, cataract, pseudo-coloboma, persistent hyaloid artery, and myopic or hypermetropic astigmatism. The appearance of the chorioretinal lesions as white to pinkish, round, non-elevated atrophic areas devoid of blood vessels resembles the lacunae in Aicardy syndrome. Due to the lack of systematic description of the lesions and significant phenotypical variability, there is an impending need for a detailed report of each case.
CASE PRESENTATION: A child with microcephaly detected in the third trimester of gestation began her following in the ophthalmology department due to a non-visually significant cataract. Shortly after, she developed nystagmus and large-angle alternating esotropia with cross-fixation. Her fundus initially showed a pallid optic disc and pigmentary changes, developing thereafter retinal lacunae and a retinal fold. Her differential diagnosis accompanied the dynamic changes in her fundus, which included congenital infections, Leber´s Congenital Amaurosis and Aicardy syndrome. At 19 months old, genetic testing identified a heterozygous mutation (c.1159 C > T, p.Arg387*) in the KIF11 gene. The patient underwent bilateral medial rectus muscle recession surgery at 2 years old for persistent esotropia, with significant improvement. Refraction revealed a hyperopic astigmatism in both eyes (+ 0.25 -2.50 × 180 OD and + 0.75 -2.00 × 170 OS). She continues to require right eye patching for 2 hours daily.
CONCLUSIONS: This case report expands the phenotypic spectrum of MCLMR by demonstrating a unique combination of retinal features which sheds new light on differential diagnosis from Aicardy syndrome. Our findings emphasize the significant phenotypic variability associated with MCLMR, particularly regarding ocular involvement. This underscores the importance of detailed clinical evaluation and comprehensive reporting of cases to improve our understanding of the disease spectrum and genotype-phenotype correlations.
Perampanel belongs to a novel class of antiseizure medications (ASMs). Studies examining the effect of hemodialysis on perampanel serum levels in clinical settings are lacking. We aimed to evaluate the changes in serum perampanel levels during hemodialysis. We studied patients with seizures who received oral perampanel between April 2020 and March 2023 and whose serum concentration of perampanel was measured before and after hemodialysis. We analyzed the serum concentrations of levetiracetam and lacosamide for comparison. Fourteen patients, with a mean age of 76.1 ± 7.88 years, were included. The dose of perampanel was 2.14 ± 1.27 mg. The hemodialysis clearance rate of perampanel, levetiracetam, and lacosamide was 0 ± 13%, 69 ± 11%, and 59.6 ± 8.2%, respectively. The post-dialysis CD ratio decreased significantly with levetiracetam but not with perampanel. Adverse but acceptable effects of perampanel were observed in two patients. The serum concentrations of several ASMs have been shown to be reduced during hemodialysis. Our study revealed that the serum perampanel concentration does not decrease during hemodialysis. Owing to the low rate of adverse effects and the stability of perampanel serum concentration during hemodialysis, perampanel could be a favorable choice as an ASM for patients with seizures undergoing hemodialysis. PLAIN LANGUAGE SUMMARY: Our study looked at how hemodialysis affects the serum levels of perampanel, a new type of medication for seizures. In 14 patients who started treatment between April 2020 and March 2023, perampanel serum levels did not decrease during hemodialysis, unlike other seizure medications. This shows that perampanel can be a good option for patients with seizures who need hemodialysis, with fewer side effects compared to other medications.
Glycolytic metabolism generates energy and intermediates for biomass production. Tumor-associated glycolysis is upregulated compared to normal tissues in response to tumor cell-autonomous or non-autonomous stimuli. The consequences of this upregulation are twofold. First, the metabolic effects of glycolysis become predominant over those mediated by oxidative metabolism. Second, overexpressed components of the glycolytic pathway (i.e. enzymes or metabolites) acquire new functions unrelated to their metabolic effects and which are referred to as "moonlighting" functions. These functions include induction of mutations and other tumor-initiating events, effects on cancer stem cells, induction of increased expression and/or activity of oncoproteins, epigenetic and transcriptional modifications, bypassing of senescence and induction of proliferation, promotion of DNA damage repair and prevention of DNA damage, antiapoptotic effects, inhibition of drug influx or increase of drug efflux. Upregulated metabolic functions and acquisition of new, non-metabolic functions lead to biological effects that support tumorigenesis: promotion of tumor initiation, stimulation of tumor cell proliferation and primary tumor growth, induction of epithelial-mesenchymal transition, autophagy and metastasis, immunosuppressive effects, induction of drug resistance and effects on tumor accessory cells. These effects have negative consequences on the prognosis of tumor patients. On these grounds, it does not come to surprise that tumor-associated glycolysis has become a target of interest in antitumor drug discovery. So far, however, clinical results with glycolysis inhibitors have fallen short of expectations. In this review we propose approaches that may allow to bypass some of the difficulties that have been encountered so far with the therapeutic use of glycolysis inhibitors.
1,217,445. Encapsulating solids. NATIONAL CASH REGISTER CO. 24 March, 1969 [12 April, 1968], No.15285/69. Heading B8C. Capsules containing solids are made by encapsulating a liquid dispersion or solution of the solid by any conventional process (mechanically, by interfacial polymerization or liquid/ liquid phase separation) and, thereafter, establishing a dispersion of the capsules in a liquid which is partially miscible with that in the capsules whereby the liquid in the capsules is removed to leave an encapsulated solid. A solid which absorbs the extracted liquid may be present in the treating liquid and the liquid may be containuously changed during the process to assist in the extraction of the encapsulated liquid. In examples aqueous dispersions of various medicaments are encapsulated in ethyl cellulose by liquid/liquid phase separation and the water is removed by treating with cyclohexane containing silica gel.
An aggregation-induced light-emitting photosensitizer material and application thereof in cleaning infected root canal relate to the field of biomedical materials. The aggregation-induced emission photo sensitizer DPA-SCP, the AIE characteristics of which provide superior photo-stability and reactive oxygen species ROS production efficiency. Under the action of low-frequency ultrasonic US, DPA-SCP mediated sonodynamic therapy SDT has strong and effective killing effect on planktonic bacteria and biological membranes, and is obviously superior to a common clinical disinfectant of 1% NaClO. In the infected root canal model, DPA-SCP mediated SDT showed comparable anti-biofilm activity to gold standard 5.25% naclo. After being excited by US, the material efficiently generates a large amount of ROS, can effectively remove bacterial biofilm in infected root canals, and shows good root canal disinfection effect. Compared with the root canal disinfectant widely applied clinically at present, the material has lower cytotoxicity, does not cause obvious thermal injury to periodontal tissues, and shows higher biological safety.